Dermata Therapeutics, Inc. (DRMA): Shareholders' Equity
$6.22M
As of 2025-12-31
$3.91M
As of 2026-09-30
+1.1%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.22M | +298.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $1.56M | -75.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $6.36M | +5.5% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $6.02M | -40.4% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $10.11M | n/m | 2023-02-21, Balance as of period end |
| 2020-12-31 | -$3.18M | n/a | 2022-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $6.22M | +298.7% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $5.58M | +228.8% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $5.27M | +756.5% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $5.79M | n/a |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $6.31M | +25.3% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $6.15M | -10.6% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | -$3.80M | n/m |
| Revium Rx. (RVRC) | 2025-12-31 | $6.88M | -65.1% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $3.21M | -13.3% |
Compare DRMA, PCSA, ACXP, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗